Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jules A. Shafer is active.

Publication


Featured researches published by Jules A. Shafer.


Nature | 2000

Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1

Yueming Li; Min Xu; Ming-Tain Lai; Qian Huang; José L. Castro; Jillian DiMuzio-Mower; Timothy Harrison; Colin Lellis; Alan Nadin; Joseph George Neduvelil; R. Bruce Register; Mohinder K. Sardana; Mark S. Shearman; Adrian Leonard Smith; Xiao-Ping Shi; Kuo-Chang Yin; Jules A. Shafer; Stephen J. Gardell

Cleavage of amyloid precursor protein (APP) by the β- and γ-secretases generates the amino and carboxy termini, respectively, of the Aβ amyloidogenic peptides Aβ40 and Aβ42—the major constituents of the amyloid plaques in the brain parenchyma of Alzheimers disease patients. There is evidence that the polytopic membrane-spanning proteins, presenilin 1 and 2 (PS1 and PS2), are important determinants of γ-secretase activity: mutations inxa0PS1 and PS2 that are associated with early-onset familial Alzheimers disease increase the production of Aβ42 (refs 4,5,6), the more amyloidogenic peptide; γ-secretase activity is reduced in neuronal cultures derived from PS1-deficient mouse embryos; and directed mutagenesis of two conserved aspartates in transmembrane segments of PS1 inactivates the ability of γ-secretase to catalyse processing of APP within its transmembrane domain. It is unknown, however, whether PS1 (which has little or no homology to any known aspartyl protease) is itself a transmembrane aspartyl protease or a γ-secretase cofactor, or helps to colocalize γ-secretase and APP. Here we report photoaffinity labelling of PS1 (and PS2) by potent γ-secretase inhibitors that were designed to function as transition state analogue inhibitors directed to the active site of an aspartyl protease. This observation indicates that PS1 (and PS2) may contain the active site of γ-secretase. Interestingly, the intact, single-chain form of wild-type PS1 is not labelled by an active-site-directed photoaffinity probe, suggesting that intact wild-type PS1 may be an aspartyl protease zymogen.


Journal of Medicinal Chemistry | 2003

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.

Christopher S. Burgey; Kyle A. Robinson; Terry A. Lyle; Philip E. Sanderson; S. Dale Lewis; Bobby J. Lucas; Julie A. Krueger; Rominder Singh; Cynthia Miller-Stein; Rebecca B. White; Bradley K. Wong; Elizabeth A. Lyle; Peter D. Williams; Craig A. Coburn; Bruce D. Dorsey; James C. Barrow; Maria T. Stranieri; Marie Holahan; Gary R. Sitko; Jacquelynn J. Cook; Daniel R. McMasters; Colleen McDonough; William M. Sanders; Audrey A. Wallace; Franklin C. Clayton; Dennis Bohn; Yvonne M. Leonard; Theodore J. Detwiler; Joseph J. Lynch; Youwei Yan


Archive | 1999

Method for treating inflammatory diseases by administering a thrombin inhibitor

Jules A. Shafer; Denise M. Visco


Archive | 2002

Beta-secretase substrates and uses thereof

James E. Bruce; Xiaoting Tang; Victor M. Garsky; Stephen F. Brady; Yueming Li; Elizabeth Chen-Dodson; Mohinder K. Sardana; Jules A. Shafer


Archive | 1996

Method of making herpes simplex type 1 mutants and mutants so produced

R. Bruce Register; Jules A. Shafer


Protein Science | 1992

Catalytically competent human and bovine ζ‐thrombin and chimeras generated from unfolded polypeptide chains

Sidney D. Lewis; Diane V. Brezniak; Jules A. Shafer; John W. Fenton


Archive | 1994

Compounds and methods for identifying activated platelets

Bohumil Bednar; Melissa S. Egbertson; Robert J. Gould; George D. Hartman; Jules A. Shafer


Archive | 2002

Beta-secretase substrate and uses thereof

James E. Bruce; Xiaoting Tang; Victor M. Garsky; Stephen F. Brady; Yueming Li; Elizabeth Chen-Dodson; Mohinder K. Sardana; Jules A. Shafer


Archive | 1999

Procede de traitement de maladies inflammatoires par administration d'un inhibiteur de la thrombine

Jules A. Shafer; Denise M. Visco


Archive | 1999

Verfahren zur behandlung von enzündlichen erkrankungen durch verabreichubg eines thrombininhibitors

Jules A. Shafer; Denise M. Visco

Collaboration


Dive into the Jules A. Shafer's collaboration.

Researchain Logo
Decentralizing Knowledge